cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway

Basic Research in Cardiology
Min ParkThomas Krieg

Abstract

The nitric oxide (NO)-protein kinase G (PKG) pathway has been known for some time to be an important target for cardioprotection against ischaemia/reperfusion injury and heart failure. While many approaches for reducing infarct size in patients have failed in the past, the advent of novel drugs that modulate cGMP and its downstream targets shows very promising results in recent preclinical and clinical studies. Here, we review main aspects of the NO-PKG pathway in light of recent drug development and summarise potential cardioprotective strategies in which cGMP is the main player.

References

Apr 18, 2002·British Journal of Pharmacology·Cherry L WainwrightPiero Del Soldato
Jan 11, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Savio P D'SouzaGary F Baxter
Sep 6, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Olaf OldenburgJames M Downey
Jan 17, 2004·The Annals of Thoracic Surgery·Kenji SangawaShunji Sano
Feb 14, 2004·Cardiovascular Research·Rainer SchulzGerd Heusch
May 11, 2004·The Journal of Biological Chemistry·Dennis J StuehrSubrata Adak
Jun 3, 2004·Proceedings of the National Academy of Sciences of the United States of America·Ennio OnginiLouis J Ignarro
Sep 14, 2004·Nature Medicine·Christian J HunterMark T Gladwin
Apr 21, 2005·The Journal of Clinical Investigation·Mark R DuranskiDavid J Lefer
Jul 23, 2005·Circulation Research·Alexandre D T CostaStuart D Critz
Nov 18, 2005·Cardiovascular Research·Toshio NishikimiHiroaki Matsuoka
Sep 7, 2006·Nature Reviews. Drug Discovery·Oleg V EvgenovJohannes-Peter Stasch
Aug 25, 2007·Science·Joseph R BurgoynePhilip Eaton
Nov 17, 2007·Cardiovascular Research·Alexandre D T CostaKeith D Garlid
Nov 27, 2007·Journal of the American College of Cardiology·Marco GuazziMaurizio D Guazzi
Apr 17, 2008·Circulation·Sei NakataNobuyuki Yanagihara
Nov 5, 2008·Circulation·Gerd HeuschRainer Schulz
Mar 25, 2009·Pharmacology & Therapeutics·Emily J Tsai, David A Kass
Jul 6, 2010·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Andreas SchäferJohann Bauersachs
Aug 10, 2010·Microcirculation : the Official Journal of the Microcirculatory Society, Inc·Clara Di FilippoMichele D'Amico
Dec 3, 2011·Circulation. Heart Failure·Xiaoyin ShanKenneth B Margulies
Aug 9, 2012·Antioxidants & Redox Signaling·Marta BuenoMark T Gladwin
Aug 9, 2012·Antioxidants & Redox Signaling·Ricardo CarnicerDavid A Kass
Mar 13, 2013·JAMA : the Journal of the American Medical Association·Margaret M RedfieldUNKNOWN RELAX Trial
May 28, 2013·Nature Medicine·Edward T ChouchaniMichael P Murphy
Mar 20, 2014·Circulation Research·Tienush RassafMalte Kelm
Jun 21, 2014·Trends in Pharmacological Sciences·Robert LukowskiFranz Hofmann
Sep 4, 2014·The New England Journal of Medicine·Mariell JessupMilton Packer

❮ Previous
Next ❯

Citations

Dec 13, 2019·Journal of Receptor and Signal Transduction Research·Yunpeng TianHaoming Song
Jan 29, 2020·Journal of Receptor and Signal Transduction Research·Peng LiQiuyun Tu
Dec 12, 2019·Drug Development Research·Natalia V NaryzhnayaPeter R Oeltgen
Oct 31, 2020·European Journal of Clinical Pharmacology·Michael BoettcherCorina Becker
Jan 20, 2021·Circulation. Heart Failure·Daniel A RichardsRobert M Blanton
Jan 25, 2020·Journal of the American College of Cardiology·Hector O VenturaMandeep R Mehra
Mar 14, 2020·Journal of Cardiovascular Pharmacology·Julia AdlerRobert Lukowski
Mar 28, 2021·Cardiovascular Toxicology·Seckin EnginSena F Sezen
Apr 26, 2021·Pharmacology & Therapeutics·Arun SamiduraiRakesh C Kukreja
May 6, 2021·Journal of Clinical and Translational Science·Araliya M SeneratVéronique L Roger
Apr 17, 2021·Proteomics·Bethany ClaridgeDavid W Greening
May 16, 2021·British Journal of Pharmacology·Robert LukowskiPeter Ruth
Sep 11, 2021·European Journal of Pharmacology·Hui-Wen YangHsiang-Yu Yang

❮ Previous
Next ❯

Software Mentioned

VICTORIA
RELAX

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.